Renovacor is specifically targeting dilated cardiomyopathy (DCM) caused by mutations in the BAG3 gene, a condition affecting over 3 million patients in the US. By developing a gene replacement therapy for DCM patients with BAG3 mutations, Renovacor aims to prevent disease progression and improve the lives of this younger population at high risk of heart failure. Their innovative precision therapies aim to target the underlying cause of genetic cardiovascular diseases and provide significant improvements in quality of life.